Kava for the treatment of generalised anxiety disorder (K-GAD): study protocol for a randomised controlled trial

Karen M Savage, Con K Stough, Gerard J Byrne, Andrew Scholey, Chad Bousman, Jenifer Murphy, Patricia Macdonald, Chao Suo, Matthew Hughes, Stuart Thomas, Rolf Teschke, Chengguo Xing, Jerome Sarris, Karen M Savage, Con K Stough, Gerard J Byrne, Andrew Scholey, Chad Bousman, Jenifer Murphy, Patricia Macdonald, Chao Suo, Matthew Hughes, Stuart Thomas, Rolf Teschke, Chengguo Xing, Jerome Sarris

Abstract

Background: Generalised anxiety disorder (GAD) is a chronic and pervasive condition that generates high levels of psychological stress, and it is difficult to treat in the long term. Current pharmacotherapeutic options for GAD are in some cases only modestly effective, and may elicit undesirable side effects. Through targeted actions on the gamma-aminobutyric acid (GABA) pathway, the South Pacific medicinal plant kava (Piper methysticum) is a non-addictive, non-hypnotic anxiolytic with the potential to treat GAD. The evidence for the efficacy of kava for treating anxiety has been affirmed through clinical trials and meta-analyses. Recent research has also served to lessen safety concerns regarding the use of kava due to hepatotoxic risk, which is reflected in a recent German court overturning the previous kava ban in that country (which may in turn influence a reinstatement by the European Union). The aim of current research is to assess the efficacy of an 'aqueous noble cultivar rootstock extract' of kava in GAD in a larger longer term study. In addition, we plan to investigate the pharmacogenomic influence of GABA transporters on response, effects of kava on gene expression, and for the first time, the neurobiological correlates of treatment response via functional and metabolic imaging.

Methods/design: This clinical trial is funded by the Australian National Health and Medical Research Council (APP1063383) and co-funded by MediHerb (Integria Healthcare (Australia) Pty. Ltd). The study is a phase III, multi-site, two-arm, 18-week, randomised, double-blind, placebo-controlled study using an aqueous extract of noble kava cultivar (standardised to 240 mg of kavalactones per day) versus matching placebo in 210 currently anxious participants with diagnosed GAD who are non-medicated. The study takes place at two sites: the Centre for Human Psychopharmacology (Swinburne University of Technology), Hawthorn, Melbourne, Australia; and the Academic Discipline of Psychiatry (The University of Queensland) based at the Royal Brisbane and Women's Hospital, Herston, Brisbane, Australia. Written informed consent will be obtained from each participant prior to commencement in the study. The primary outcome is the Structured Interview Guide for the Hamilton Anxiety Rating Scale (SIGH-A). The secondary outcomes involve a range of scales that assess affective disorder symptoms and quality of life outcomes, in addition to the study of mediating biomarkers of response (assessed via genomics and neuroimaging).

Discussion: If this study demonstrates positive findings in support of the superiority of kava over placebo in the treatment of GAD, and also is shown to be safe, then this plant-medicine can be considered a 'first-line' therapy for GAD. Genomic and neuroimaging data may reveal clinical response patterns and provide more evidence of the neurobiological activity of the plant extract.

Trial registration information: ClinicalTrials.gov: NCT02219880 Date: 13 August 2014:.

Figures

Fig. 1
Fig. 1
Active constituents of kava
Fig. 2
Fig. 2
Kava studies timeline summary
Fig. 3
Fig. 3
Clinical trial flowchart

References

    1. Stein D. Generalised anxiety disorder. Rethinking diagnosis and rating. CNS Spectr. 2005;10(12):930–4.
    1. American Psychiatric Association (APA) Diagnostic and statistical manual of mental disorders. Washington, DC: American Psychiatric Association; 2013.
    1. Baxter AJ, Scott KM, Vos T, Whiteford HA. Global prevalence of anxiety disorders: a systematic review and meta-regression. Psychol Med. 2013 May;43(5):897-910.
    1. Wittchen HU, Jacobi F, Rehm J, et al. The size and burden of mental disorders and other disorders of the brain in Europe. Eur Neuropsychopharmacol. 2011;21(9):655–79. doi: 10.1016/j.euroneuro.2011.07.018.
    1. McEvoy PM, Grove R, Slade T. Epidemiology of anxiety disorders in the Australian general population: findings of the 2007 Australian National Survey of Mental Health and Wellbeing. Aust N Z J Psychiatry. 2011;45(11):957–67. doi: 10.3109/00048674.2011.624083.
    1. Department of Health and Aging. The mental health of Australians: anxiety disorders in Australia. 2012.
    1. Hoffman EJ, Mathew SJ. Anxiety disorders: a comprehensive review of pharmacotherapies. Mt Sinai J Med. 2008;75(3):248–62. doi: 10.1002/msj.20041.
    1. Hidalgo RB, Tupler LA, Davidson JR. An effect-size analysis of pharmacologic treatments for generalized anxiety disorder. J Psychopharmacol. 2007;21(8):864–72. doi: 10.1177/0269881107076996.
    1. Papakostas G. Tolerability of modern antidepressants. J Clin Psychiatry. 2008;69(Suppl 1):8–13.
    1. Rickels K, Rynn M. Pharmacotherapy of generalized anxiety disorder. J Clin Psychiatry. 2002;63(Suppl 14):9–16.
    1. Baldwin DS, Ajel KI, Garner M. Pharmacological treatment of generalized anxiety disorder. Curr Top Behav Neurosci. 2010;2:453–67. doi: 10.1007/7854_2009_2.
    1. Cuijpers P, Sijbrandij M, Koole S, Huibers M, Berking M, Andersson G. Psychological treatment of generalized anxiety disorder: a meta-analysis. Clin Psychol Rev. 2014;34:130–40. doi: 10.1016/j.cpr.2014.01.002.
    1. Hunot V, Churchill R, Teixeira V, Silva de Lima M. Psychological therapies for generalised anxiety disorder (Review). Cochrane Database of Systematic Reviews. 2007; 24;(1):CD001848
    1. Gunter RW, Whittal ML. Dissemination of cognitive-behavioral treatments for anxiety disorders: Overcoming barriers and improving patient access. Clin Psychol Rev. 2010;30(2):194–202. doi: 10.1016/j.cpr.2009.11.001.
    1. Weisberg RB, Dyck I, Culpepper L, Keller MB. Psychiatric treatment in primary care patients with anxiety disorders: a comparison of care received from primary care providers and psychiatrists. Am J Psychiatry. 2007;164(2):276–82. doi: 10.1176/ajp.2007.164.2.276.
    1. Goldberg D. Epidemiology of mental disorders in primary care settings. Epidemiol Rev. 1995;17:182–90.
    1. Koerner N. The importance of taking an integrative approach to the study of worry, intolerance of uncertainty, and generalized anxiety disorder. Can Psychol/Psychol Can. 2014;55(1):44–7. doi: 10.1037/a0035552.
    1. Starcevic V, Portman ME, Beck AT. Generalized anxiety disorder: between neglect and an epidemic. J Nervous Mental Dis. 2012;200:664–7. doi: 10.1097/NMD.0b013e318263f947.
    1. Lebot V, Merlin M, Lindstrom L. Kava: the Pacific drug. New Haven, Connecticut: Yale University Press; 1992
    1. Singh YN. Kava: an overview. J Ethnopharmacol. 1992;37(1):13–45. doi: 10.1016/0378-8741(92)90003-A.
    1. Mathews JM, Etheridge AS, Valentine JL, et al. Pharmacokinetics and disposition of the kavalactone kawain: interaction with kava extract and kavalactones in vivo and in vitro. Drug Metab Dispos. 2005;33:1555–63. doi: 10.1124/dmd.105.004317.
    1. Holm E, Staedt U, Hepp J, et al. Untersuchungen zum Wirkungsprofil von D, L-kavain. Arzneim Forsch. 1991;41(7):673–83.
    1. Magura EI, Kopanitsa MV, Gleitz J, et al. Kava extract ingredients, (+)-methysticin and (+/−)-kavain inhibit voltage-operated Na(+)-channels in rat CA1 hippocampal neurons. Neuroscience. 1997;81(2):345–51. doi: 10.1016/S0306-4522(97)00177-2.
    1. Gleitz J, Beile A, Peters T. (+/−)-Kavain inhibits veratridine-activated voltage-dependent Na(+)-channels in synaptosomes prepared from rat cerebral cortex. Neuropharmacol. 1995;34(9):1133–8. doi: 10.1016/0028-3908(95)00090-S.
    1. Martin HB, McCallum M, Stofer WD, et al. Kavain attenuates vascular contractility through inhibition of calcium channels. Planta Med. 2002;68(9):784–9. doi: 10.1055/s-2002-34443.
    1. Walden J, von Wegerer J, Winter U, et al. Effects of kawain and dihydromethysticin on field potential changes in the hippocampus. Prog Neuropsychopharmacol Biol Psychiatry. 1997;21(4):697–706. doi: 10.1016/S0278-5846(97)00042-0.
    1. Jussofie A, Schmiz A, Hiemke C. Kavapyrone enriched extract from Piper methysticum as modulator of the GABA binding site in different regions of rat brain. Psychopharmacology (Berl) 1994;116(4):469–74. doi: 10.1007/BF02247480.
    1. Uebelhack R, Franke L, Schewe HJ. Inhibition of platelet MAO-B by kava pyrone-enriched extract from Piper methysticum Forster (kava-kava) Pharmacopsychiatry. 1998;31(5):187–92. doi: 10.1055/s-2007-979325.
    1. Wu D, Yu L, Nair M, DeWitt D, et al. Cyclooxygenase enzyme inhibitory compounds with antioxidant activities from Piper methysticum (kava kava) roots. Phytomedicine. 2002;9:41–7. doi: 10.1078/0944-7113-00068.
    1. Baum SS, Hill R, Rommelspacher H. Effect of kava extract and individual kavapyrones on neurotransmitter levels in the nucleus accumbens of rats. Prog Neuropsychopharmacol Biol Psychiatry. 1998;22(7):1105–20. doi: 10.1016/S0278-5846(98)00062-1.
    1. Seitz U, Schule A, Gleitz J. [3H]-monoamine uptake inhibition properties of kava pyrones. Planta Med. 1997;63(6):548–9. doi: 10.1055/s-2006-957761.
    1. Thompson R, Ruch W, Hasenohrl RU. Enhanced cognitive performance and cheerful mood by standardized extracts of Piper methysticum (Kava-kava) Hum Psychopharmacol. 2004;19(4):243–50. doi: 10.1002/hup.581.
    1. Sarris J, Scholey A, Schweitzer I, et al. The acute effects of kava and oxazepam on anxiety, mood, neurocognition, and genetic correlates: a randomized, placebo-controlled, double-blind study. Hum Psychopharmacol. 2012;27(3):262–9. doi: 10.1002/hup.2216.
    1. Pittler MH, Ernst EE. Efficacy of kava extract for treating anxiety: systematic review and meta-analysis. J Clin Psychopharm. 2000;20(1):84–9. doi: 10.1097/00004714-200002000-00014.
    1. Sarris J, Laporte E, Schweitzer I. Kava: a comprehensive review of efficacy, safety, and psychopharmacology. Aust N Z J Psychiatry. 2011;45(1):27–35. doi: 10.3109/00048674.2010.522554.
    1. Sarris J, Kavanagh D, Byrne G, Bone K, Adams J, Deed G. The Kava Anxiety Depression Spectrum Study (KADSS): a randomized, placebo-controlled, cross-over trial using an aqueous extract of Piper methysticum. Psychopharmacol. 2009;205(3):399–407. doi: 10.1007/s00213-009-1549-9.
    1. Sarris J, Stough C, Bousman C, et al. Kava in the treatment of generalized anxiety disorder: a double-blind, randomized, placebo-controlled study. J Clin Psychopharmacol. 2013;33(5):643–8. doi: 10.1097/JCP.0b013e318291be67.
    1. Hamilton M. The assessment of anxiety states by rating. Br J Med Psychol. 1959;32:50–5. doi: 10.1111/j.2044-8341.1959.tb00467.x.
    1. Beck AT, Epstein N, Brown G, Steer RA. An inventory for measuring clinical anxiety: psychometric properties. J Consult Clin Psychol. 1988;56(6):893–7. doi: 10.1037/0022-006X.56.6.893.
    1. Meyer TJ, Miller ML, Metzger RL, Borkovec TD. Development and validation of the Penn State Worry Questionnaire. Behav Res Ther. 1990;28:487–95. doi: 10.1016/0005-7967(90)90135-6.
    1. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry. 1979;134(4):382–9. doi: 10.1192/bjp.134.4.382.
    1. Skevington SM, Lofty M, O’Connell KA. The World Health Organization’s WHOQOL-BREF quality of life assessment: psychometric properties and results of the international field trial. A report from the WHOQOL group. Qual Life Res. 2004;13(2):299–310. doi: 10.1023/B:QURE.0000018486.91360.00.
    1. Holmes TH, Rahe RH. The Social Re-adjustment Rating Scale. J Psychosom Res. 1967;11:213–8. doi: 10.1016/0022-3999(67)90010-4.
    1. Kessler RC, Andrews G, Colpe LJ, et al. Short screening scales to monitor population prevalences and trends in non-specific psychological distress. Psychol Med. 2002;32:959–976. doi: 10.1017/S0033291702006074.
    1. McGahuey CA, Gelenberg AJ, Laukes CA, et al. The Arizona Sexual Experience Scale (ASEX): reliability and validity. J Sex Marital Ther. 2000;26:25–40. doi: 10.1080/009262300278623.
    1. Lecrubier Y, Sheehan D, Weiller E, Amorim P, Bonora I, Sheehan K, et al. The M.I.N.I. International Neuropsychiatric Interview (M.I.N.I.). A short diagnostic structured interview: reliability and validity according to the CIDI. Eur Psychiatry. 1997;12:224–31. doi: 10.1016/S0924-9338(97)83296-8.
    1. Shear MK, Vander Bilt J, Rucci P, Endicott J, Lydiard B, Oto MW, et al. Reliability and validity of a structured interview guide for the Hamilton Anxiety Rating Scale (SIGH-A) Depress Anxiety. 2001;13:166–78. doi: 10.1002/da.1033.
    1. Maier W, Buller R, Philipp M, Heuser I. The Hamilton Anxiety Scale: reliability, validity and sensitivity to change in anxiety and depressive disorders. J Affect Disord. 1988;14:61–8. doi: 10.1016/0165-0327(88)90072-9.
    1. Brown TA, Antony MM, Barlow DH. Psychometric properties of the Penn State Worry Questionnaire in a clinical anxiety disorders sample. Behav Res Ther. 1992;30:33–7. doi: 10.1016/0005-7967(92)90093-V.
    1. Williams JBW, Kobak KA. Development and reliability of a structured interview guide for the Montgomery-Asberg Depression Rating Scale (SIGMA) Br J Psychiatry. 2008;192(1):52–8. doi: 10.1192/bjp.bp.106.032532.
    1. Gustavsson JP, Bergman H, Edman G, Ekaselius L, von Knorring L, Linder J. Swedish universities Scales of Personality (SSP) – Manual 2.0. Karolinska Institute & Uppsala University, Stockholm, Sweden. 2000.
    1. Lang PJ, Bradley MM, Cuthbert BN. International Affective Picture System (IAPS): affective ratings of pictures and instruction manual. Technical Report A-8. Gainesville, FL: University of Florida; 2008.
    1. Spielberger CD, Gorsuch RL, Lushene R, Vagg PR, Jacobs GA. Manual for the State-Trait Anxiety Inventory. Palo Alto, CA: Consulting Psychologists Press; 1983.
    1. Rae CD. A guide to the metabolic pathways and function of metabolites observed in human brain 1-H magnetic resonance spectra. Neurochem Res. 2014;39:1–36. doi: 10.1007/s11064-013-1199-5.
    1. IBM SPSS Statistics for Windows, Version 22.0. Armonk, NY: IBM Corp; 2013.
    1. Uppman M. The reliability of GABA measurements in the human brain by MRS at 3T. 2010.
    1. Heberlein K, Brown MA. Spectral editing with SVS. Applications Guide. Munich, Germany: Siemens Corporation; 2009.
    1. Wood SJ, Kennedy D, Phillips LJ, Seal ML, et al. Hippocampal pathology in individuals at ultra-high risk for psychosis: a multi-modal magnetic resonance study. Neuroimage. 2010;52:62–8. doi: 10.1016/j.neuroimage.2010.04.012.
    1. Thompson CM, Shure L. MathWorks. Bioinformatics Toolbox: User’s Guide (R2012a). Mathworks:Massachusetts, USA; 1995.
    1. Berger GE, Wood SJ, Wellard RM, et al. Ethyl-eicosapentaenoic acid in first episode psychosis. A 1H-MRS study. Neuropsychopharmacology. 2008;33(10):2467. doi: 10.1038/sj.npp.1301628.
    1. Ernst E. A re-evaluation of kava (Piper methysticum) Br J Clin Pharmacol. 2007;64(4):415–7. doi: 10.1111/j.1365-2125.2007.02932.x.
    1. Teschke R. Kava hepatotoxicity — a clinical review. Ann Hepatol. 2010;9(3):251–5.
    1. Sarris J, Teschke R, Stough C, et al. Re-introduction of kava (Piper methysticum) to the EU: is there a way forward? Planta Med. 2011;77:107–10. doi: 10.1055/s-0030-1250290.
    1. Coulter D. Assessment of the risk of hepatotoxicity with kava products. WHO appointed committee. Geneva: World Health Organization; 2007.
    1. Levine J, Schooler N. SAFTEE (Systematic Assessment for Treatment of Emergent Events). A new technique for detecting side effects in clinical trials. Clin Neuropharmacol. 1984;7(1):861–77.
    1. Chan A, Tetzlaff JM, Altman DG, Laupacis A, Gøtzsche PC, Krleža-Jerić K, et al. SPIRIT 2013 Statement: defining standard protocol items for clinical trials. Ann Intern Med. 2013;158:200–7. doi: 10.7326/0003-4819-158-3-201302050-00583.
    1. Rothman DL, Hyder F, Sibson N, et al. In vivo magnetic resonance spectroscopy studies of the glutamate and GABA neurotransmitter cycles and functional neuroenergetics. In: Davis KL, Charney D, Coyle JT, Nemeroff CB, et al., editors. Neuropsychopharmacology: the fifth generation of progress. American College of Neuropsychopharmacology. 2002.
    1. Puts NAJ, Edden RAE. In vivo magnetic resonance spectroscopy of GABA: a methodological review. Prog Magn Reson Spectrosc. 2012;60:29–41. doi: 10.1016/j.pnmrs.2011.06.001.
    1. Etkin A, Wager TD. Functional neuroimaging of anxiety: a meta-analysis of emotional processing in PTSD, social anxiety disorder, and specific phobia. Am J Psychiatry. 2007;164:10. doi: 10.1176/appi.ajp.2007.07030504.
    1. Mullins PG, et al. Current practice in the use of MEGA-PRESS spectroscopy for the detection of GABA. Neuroimage. 2013;86:43–52. doi: 10.1016/j.neuroimage.2012.12.004.
    1. Allman JM, Hakeem A, Erwein JM, Nimchinsky E, Hof P. The anterior cingulate cortex. The evolution of an interface between emotion and cognition. Ann N Y Acad Sci. 2001;935:107–17. doi: 10.1111/j.1749-6632.2001.tb03476.x.
    1. Bush G, Luu P, Posner MI. Cognitive and emotional influences in anterior cingulate cortex. Trends Cogn Sci. 2000;4:215–22. doi: 10.1016/S1364-6613(00)01483-2.
    1. Critchley HD, Mathias CJ, Josephs O, O’Doherty J, Zanini S, Dewar BK, et al. Human cingulate cortex and autonomic control: converging neuroimaging and clinical evidence. Brain. 2003;126:2139–52. doi: 10.1093/brain/awg216.
    1. Etkin A, Prate KE, Hoeft F, Menon V, Schatzberg AF. Failure of anterior cingulate activation and connectivity with the amygdala during implicit regulation of emotional processing in generalised anxiety disorder. Am J Psychiatry. 2010;167:545–54. doi: 10.1176/appi.ajp.2009.09070931.
    1. Luu P, Pederson SM. The anterior cingulate cortex: regulating actions in context. In: Posner MI, editor. Cognitive neuroscience of attention. New York: Guilford Publication Inc; 2004.
    1. Murphy FC, Nimmo-Smith I, Lawrence AD. Functional neuroanatomy of emotions: a meta-analysis. Cogn Affect Behav Neur. 2003;3(3):207–33. doi: 10.3758/CABN.3.3.207.
    1. Schienle A, Hettema JM, Caceda R, Nemeroff CB. Neurobiology and genetics of generalised anxiety disorder. Psychiatr Ann. 2011;41(2):113–23.
    1. Vogt BA, Finch DM, Olson CR. Functional heterogeneity in cingulate cortex: the anterior executive and posterior evaluative regions. Cereb Cortex. 1992;2(6):435–43.
    1. Wegner DM, Schneider DJ, Carter SL, White TL. Paradoxical effects of thought suppression. J Pers Soc Psychol. 1987;63:903–12. doi: 10.1037/0022-3514.63.6.903.

Source: PubMed

Patrocinadores e Colaboradores

Condições médicas

Intervenções de drogas

3
Se inscrever